engleski

Naturally occurring peptides for gastroprotection: stable gastric pentadecapeptide BPC 157

We focused on the stable gastric pentadecapeptide BPC 157 as an essential cytoprotective agent. Noteworthy, the category of cytoprotective drugs was largely expanded since original Robert’s description (stomach cell protection against gastric lesion induced by one gastric acid secretion (GAS) non-dependent necrotizing challenge) to different antiulcer agents (anticholinergics, DA-agonists, H2 blockers, PPIs) including peptidergic agents. However, the agents had been mainly termed to be cytoprotective, without investigating all aspects of cytoprotection: (i) gastrectomy (absent GAS, thereby, GAS-independency), (ii) angiogenesis, (iii) adaptive cytoprotection (depending on endogenous and/or exogenous nature of small and strong irritants), (iv) wound healing potential, in addition to gastric ulcer, (v) organoprotection (cell protection relevant in other organs lesions). To resolve this, we showed that anticholinergics, DA-agonists, H2 blockers, PPIs inhibit cysteamine duodenal ulcer in gastrectomized rats, all exhibit angiogenic potential. We also demonstrated that anticholinergics and H2 blockers are cytoprotective while PPIs are both cytoprotective and adaptive cytoprotective but only with exogenous irritants. Also interestingly, in rats with gastrocutaneous fistulas, after some delay, anticholinergics, H2 blockers, PPIs firstly start to heal skin lesion, and then later gastric lesions as well, but only anticholinergics may induce fistulas healing. In this, gastric pentadecapeptide BPC 157 is effective in gastrectomized rats, angiogenic potential higher than standard antiulcer agents, presenting with both cytoprotective and adaptive cytoprotective potential against both endogenous and exogenous irritants. In rats with gastrocutaneous fistulas, BPC 157 promptly reduces both skin and gastric lesions and induces fistula closure, thus presenting much higher wound healing potential in addition to gastric ulcer than standards. Besides, along with a special structure (GEPPPGKPADDAGLV, MW 1419), it may be particularly important as a small anti-ulcer peptide in the whole GI tract (non degraded in human gastric juice more than 24h), liver and pancreas lesion, efficient in inflammatory bowel disease trials (PL 14736) and various wound treatment, no toxicity reported. In rats with esophagitis and failed function of both lower esophageal sphincter (LES) and pyloric sphincter (PS), BPC 157 increased pressure in both sphincter till normal values and reduced esophagitis.

BPC 157; cytoprotective agent; gastroprotection

nije evidentirano